0000000000109604

AUTHOR

ÁNgela Rojas

showing 2 related works from this author

International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis

2020

Background & Aims: Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma (HCC) under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, prevalence, tolerability, and outcome of sorafenib in this population. Methods: We report a multicenter study comprising patients from Latin America and Europe. Patients treated with sorafenib were enrolled; demographics, dose modifications, adverse events (AEs), treatment duration, and outcome of patients undergoing dialysis were recorded. Results: As of March 2018, 6156 HCC patients were treated in 44 centres and 22 patients were concomitantly under dial…

NiacinamidesafetySorafenibdialysimedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomamedicine.medical_treatmentPopulationadverse eventAntineoplastic Agentssurvival03 medical and health sciences0302 clinical medicineRenal DialysisInterquartile rangeInternal medicineHepatocellular carcinoma; adverse events; dialysis; safety; sorafenib; survivalmedicineHumanseducationDialysisAgededucation.field_of_studyHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsRetrospective cohort studyHepatitis CSorafenibmedicine.diseaseadverse eventsEuropeTreatment OutcomeTolerability030220 oncology & carcinogenesisHepatocellular carcinomadialysissorafenib030211 gastroenterology & hepatologybusinessmedicine.drugLiver International
researchProduct

Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study

2022

Background & Aims Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis…

Settore MED/12 - GastroenterologiaCarcinoma HepatocellularHepatologyHepatocellular carcinomaSARS-CoV-2Liver NeoplasmsCOVID-19hepatocellular carcinomamortalityCohort Studiesliver cancerCOVID-19 TestingCross-Sectional Studiesmortality.HumansMortalityLiver cancerRetrospective Studies
researchProduct